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Dear Editors,
In order to highlight the Brazilian participation in the GRAPPA 
meeting, we submit the following letter:
Psoriatic arthritis (PsA) was identiﬁ ed as a speciﬁ c entity 
after the studies by Verna Wright in Leeds, United Kingdom. 
By the late 1950s, Verna already acknowledged that erosive 
arthritis in the absence of serum rheumatoid factor and in as-
sociation with intense inﬂ ammatory activity was a different 
clinical condition from rheumatoid arthritis and osteoarthritis.1 
A few years later, John Moll, also from Leeds, together with 
Verna Wright established through a classical publication the 
classiﬁ cation criteria for PsA, incorporating the ﬁ ve different 
types of clinical presentation of the disease.2 It is worth em-
phasizing that Verna Wright created the Unit of Rheumatology 
of Leeds in 1964, which concentrated the studies on PsA. In 
1980, he was the leading ﬁ gure of the Brazilian Congress of 
Rheumatology in Belo Horizonte, invited by Professor Paulo 
Madureira, and, in 1988, Verna Wright died.
Along with the evolution of epidemiological and physio-
pathological knowledge, the concept of “psoriatic disease” as 
a systemic inﬂ ammatory condition has grown, characterized 
by clinical manifestations involving different organs and as-
sociated with speciﬁ c comorbidities, such as diabetes mellitus 
and hypertension. Thus, considering the need to increase the 
interaction between specialists and the understanding about 
PsA from the rheumatological and dermatological viewpoints, 
multidisciplinary meetings became a reality and stimulated the 
creation of the Group for Research and Assessment of Psoriasis 
and Psoriatic Arthritis (GRAPPA) in 2003.3 
 The group is an international non-proﬁ t organization with 
educational and scientiﬁ c purposes. It promotes cooperation 
between several medical disciplines, and currently consists of 
about 320 prominent researchers and opinion leaders among 
rheumatologists, dermatologists, radiologists, geneticists, epi-
demiologists, and representatives from patient service leagues 
and from the biopharmaceutical industry. Approximately 60% 
of its participants live and work outside North America. The ﬁ rst 
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ofﬁ cial GRAPPA meeting was held in New York in August 2003, 
when initial research priorities were established. To achieve 
its objectives and goals, GRAPPA has created the following 
committees responsible for distinct and relevant areas to the 
management of patients with psoriasis (PsO) and PsA: Peripheral 
Joint Assessment; Spinal Assessment; Publications; Imaging; 
Website; Quality of Life/Function/Participation; Governance; 
Histology/Immunohistochemistry; and Treatment Guidelines. 
The identiﬁ cation of adequate biomarkers and clinical instru-
ments to assess patients with PsA, validated for clinical practice 
and for clinical studies, is fundamental and mandatory. Predictive 
biomarkers of articular involvement in patients with PsO and of 
articular damage in PsA are being jointly developed by GRAPPA 
and the Outcome Measures in Rheumatology Clinical Trials 
(OMERACT). In addition, speciﬁ c instruments for diagnosis, 
follow-up, and treatment, essential in approaching patients with 
“psoriatic disease”, are also being developed. 
The accomplishments of GRAPPA were as follows: 
publications; evidence-based reviews; prioritized domains 
of inquiry within PsA and PsO research through consensus 
process ﬁ nalized at OMERACT; intranet launch, which 
provides a way to communicate and post documents; in-
ternational dermatology and rheumatology meetings; and 
annual meetings at various countries. Research projects with 
international collaboration are being developed, focusing on: 
reﬁ nement and validation of arthritis outcome measures in 
PsA; development of instruments to assess quality of life, 
function, and participation; standardization of histologic 
and immunohistochemistry assessments of skin and syno-
vial membrane; updated criteria for classiﬁ cation of PsA 
(CASPAR); imaging in PsA; socioeconomic impact and ef-
fect of therapy; production of a video/web-based assessment 
training; and response measure project. 
The GRAPPA’s goals are as follows: provide a forum 
for networking and communication between its members, 
industry, patient service leagues and regulatory agencies; 
provide the opportunity for in-person meetings and an intranet 
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communication to share knowledge, research ﬁ ndings, and 
develop or conduct collaborative research, education, and 
other projects; develop and validate criteria for the deﬁ nition 
of PsA; review, develop and validate effective and feasible 
outcome measures for the assessment of PsA and PsO; pro-
mote the development of registries of patients; work closely 
with representatives of patients to promote public education 
and awareness of PsA and PsO; work closely with represen-
tatives of pharmaceutical companies to promote and conduct 
research on effective therapies for PsA and PsO; work closely 
with representatives of regulatory agencies to establish ap-
propriate guidelines for approval of new therapies; work with 
other professional bodies, such as the American College of 
Rheumatology, American Academy of Dermatology, and 
OMERACT, to promote knowledge of research about PsA 
and PsO within the context of the respective disciplines; and 
to develop treatment guidelines for governmental and other 
interested parties.
In fact, in recent years, GRAPPA has made an extraordinary 
effort to foster educational and scientiﬁ c meetings, which facili-
tate the development and dissemination of information related to 
PsO and PsA among different medical specialists who work in 
these areas, such as rheumatologists and dermatologists. Thus, 
enhancement in research, diagnosis, follow-up, and treatment of 
PsO and PsA has been achieved. Recently, in September 2010, 
thanks to the efforts of the Brazilian GRAPPA members and the 
high receptivity of the Brazilian Society of Rheumatology, it was 
possible to hold the ﬁ rst GRAPPA meeting in Latin America 
(GRAPPA CBR 2010) during the XXVIII Brazilian Congress of 
Rheumatology, in the city of Porto Alegre, RS, Brazil. This ﬁ rst 
GRAPPA meeting in Latin America gathered several Brazilian 
participants, in addition to ten invited foreign speakers. Since 
that event, a Brazilian harmonious and recognized group has 
been formed inside GRAPPA, and already participates in some 
of the ongoing projects. Currently this group is deﬁ ning goals 
for the future, which allow its more active participation inside 
GRAPPA, well aligned with the Spondyloarthritis Committee 
of the Brazilian Society of Rheumatology.
 These events and joint studies gathering rheumatologists, 
other specialists, and professionals willing to contribute to 
knowledge about PsO and PsA have been aimed at providing 
scientiﬁ c evidence for advances in clinical and therapeutic 
management, enabling the enhancement of the quality of life 
and prognosis of patients with PsA. Thus, systematic joint 
meetings should strengthen the presence of the Brazilian rheu-
matology in GRAPPA worldwide, which currently comprises 
three dermatologists (Flávia Lisboa, Marcia Ramos-e-Silva, 
and Cid Sabbag) and eight rheumatologists (Roberto Acayaba 
de Toledo and the seven authors of this letter). As members, 
we participate in several annual meetings and are encouraged 
to take part in projects and speciﬁ c committees.
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